POLYMEDIX, INC Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 79 rows, 79 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2012-03-26: Reporting owner Swirsky Douglas J; Form 4; Security Stock Option (Right to purchase); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2012-03-26: Reporting owner O MALLEY SHAUN; Form 4; Security Stock Option (Right to purchase); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2012-03-26: Reporting owner Loren Stefan; Form 4; Security Stock Option (Right to purchase); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2012-03-26: Reporting owner Lewis Michael E; Form 4; Security Stock Option (Right to purchase); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2012-03-26 | Swirsky Douglas J Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | O MALLEY SHAUN Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Loren Stefan Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Lewis Michael E Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | BANK RICHARD W Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | ANDERSON BRIAN Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,000 37,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Scott Richard W Officer (VP Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +520,000 520,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Smith Edward F Officer (CFO) | 4 | sTOCK oPTION (rIGHT TO bUY) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +432,000 432,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Korczak Bozena Officer (VP Drug Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +173,000 173,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | JORGENSEN DANIEL Officer (Sr VP Clinical Dev & CMO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +255,000 255,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2012-03-26 | Landekic Nicholas Director, Officer (CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,726,000 1,726,000 owned after | $1.22 exercise price | 2012-03-28 | |
| 2011-08-29 | JORGENSEN DANIEL Officer (Sr VP Clin Dev/Chief Med Off) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $0.55 exercise price | 2011-08-31 | |
| 2011-01-20 | Lewis Michael E Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-25 | |
| 2011-01-20 | Smith Edward F Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +240,000 240,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | SLATTERY FRANK P JR Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | Landekic Nicholas Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +540,000 540,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | Scott Richard W Officer (VP of Research) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +215,000 215,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | HELMLING STEFFEN A. Other (VP of Business Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +100,000 100,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | Korczak Bozena Officer (VP of Drug Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +405,000 405,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | O MALLEY SHAUN Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | BANK RICHARD W Director | 4 | Stock Option (Right to purchase Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | Swirsky Douglas J Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | Loren Stefan Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2011-01-20 | ANDERSON BRIAN Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,000 25,000 owned after | $0.93 exercise price | 2011-01-24 | |
| 2010-11-15 | HELMLING STEFFEN A. Officer (VP of Business Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +300,000 300,000 owned after | $1.01 exercise price | 2010-11-17 | |
| 2010-09-02 | Lewis Michael E Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | O MALLEY SHAUN Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | BANK RICHARD W Director | 4 | Stock Option (Right to purchase) Derivative · Direct | P Open market or private purchase of non-derivative or derivative security | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | ANDERSON BRIAN Director | 4 | Stock Option (Right to purchase Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | Swirsky Douglas J Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | SLATTERY FRANK P JR Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-09-02 | Loren Stefan Director | 4 | Stock Option (Right to purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.76 exercise price | 2010-09-07 | |
| 2010-07-30 | McAllister R Eric Officer (VP Clin.Dev., Ch.Med.Officer) | 4 | Employee Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $0.90 exercise price | 2010-08-04 | |
| 2010-07-30 | Landekic Nicholas Director, Officer (President and CEO) | 4 | Employee Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +187,500 187,500 owned after | $0.90 exercise price | 2010-08-04 | |
| 2010-05-14 | Scott Richard W Officer (VP Research) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $0.97 exercise price | 2010-05-19 | |
| 2010-02-24 | McAllister R Eric Officer (VP Clin Dev., Ch. Med. Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +350,000 350,000 owned after | $1.05 exercise price | 2010-02-26 | |
| 2010-02-24 | Scott Richard W Officer (VP Research) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $1.05 exercise price | 2010-02-26 | |
| 2010-02-24 | Korczak Bozena Officer (VP, Drug Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $1.05 exercise price | 2010-02-26 | |
| 2010-02-24 | Smith Edward F Officer (VP Fin, CFO and Secretary) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +325,000 325,000 owned after | $1.05 exercise price | 2010-02-26 | |
| 2010-02-24 | Landekic Nicholas Director, Officer (President and CEO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,750,000 1,750,000 owned after | $1.05 exercise price | 2010-02-26 | |
| 2009-07-01 | Swirsky Douglas J Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $0.70 exercise price | 2009-07-06 | |
| 2009-02-02 | Lewis Michael E Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $0.99 exercise price | 2009-02-03 | |
| 2009-02-02 | KELLEY WILLAM N Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $0.99 exercise price | 2009-02-03 | |
| 2009-02-02 | O MALLEY SHAUN Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $0.99 exercise price | 2009-02-03 | |
| 2009-02-02 | SLATTERY FRANK P JR Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +38,500 38,500 owned after | $0.99 exercise price | 2009-02-03 | |
| 2008-12-30 | Scott Richard W Officer (VP Research) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +225,000 225,000 owned after | $1.18 exercise price | 2008-12-31 | |
| 2008-12-30 | Korczak Bozena Officer (VP, Drug Development) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 0 owned after | $1.18 exercise price | 2008-12-31 | |
| 2008-12-30 | Smith Edward F Officer (VP Fin, CFO & Secretary) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +325,000 325,000 owned after | $1.18 exercise price | 2008-12-31 | |
| 2008-12-30 | McAllister R Eric Officer (VP Clin.Dev., Ch.Med.Officer) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +500,000 500,000 owned after | $1.18 exercise price | 2008-12-31 | |
| 2008-12-30 | Landekic Nicholas Director, Officer (President and CEO) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,000,000 1,000,000 owned after | $1.18 exercise price | 2008-12-31 | |
| 2008-12-02 | Ford James Gregory Officer (VP of Business Development) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +400,000 0 owned after | $0.88 exercise price | 2008-12-11 | |
| 2008-07-31 | BANK RICHARD W Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $0.80 exercise price | 2008-08-04 | |
| 2008-07-31 | Loren Stefan Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $0.80 exercise price | 2008-08-04 | |
| 2008-01-23 | Scott Richard W Officer (VP Research) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $1.10 exercise price | 2008-01-25 | |
| 2008-01-23 | Landekic Nicholas Director, Officer (President and CEO) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +600,000 600,000 owned after | $1.10 exercise price | 2008-01-25 | |
| 2008-01-23 | McAllister R Eric Officer (VP Clin.Dev., Ch.Med.Officer) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +200,000 200,000 owned after | $1.10 exercise price | 2008-01-25 | |
| 2008-01-23 | Smith Edward F Officer (VP Fin, CFO & Secretary) | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +125,000 125,000 owned after | $1.10 exercise price | 2008-01-25 | |
| 2008-01-23 | ANDERSON BRIAN Director | 4 | Stock Option (Right to Purchase) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 150,000 owned after | $1.10 exercise price | 2008-01-25 | |
| 2007-11-13 | Korczak Bozena Officer (VP, Drug Development) | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +250,000 0 owned after | $0.98 exercise price | 2007-11-14 | |
| 2007-09-11 | Lewis Michael E Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 330,000 owned after | $1.10 exercise price | 2007-09-13 | |
| 2007-09-11 | KELLEY WILLAM N Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 330,000 owned after | $1.10 exercise price | 2007-09-13 | |
| 2007-09-11 | DELAPE FRANK M Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 330,000 owned after | $1.10 exercise price | 2007-09-13 | |
| 2007-09-11 | SLATTERY FRANK P JR Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 330,000 owned after | $1.10 exercise price | 2007-09-13 | |
| 2007-09-11 | O MALLEY SHAUN Director | 4 | Stock Option Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +150,000 330,000 owned after | $1.10 exercise price | 2007-09-13 | |
| 2007-03-16 holding as of filing | McAllister R Eric Officer (VP, Clinical Development) | 3 | Stock Option (right to buy) Derivative · Direct | Holding | $3.50 exercise price | 2007-03-16 | ||
| 2007-02-05 | Smith Edward F Officer (Chief Financial Officer) | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +30,000 30,000 owned after | $2.85 exercise price | 2007-05-08 | |
| 2007-02-05 | Scott Richard W Officer (Vice President of Research) | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $2.85 exercise price | 2007-05-08 | |
| 2007-02-05 | Landekic Nicholas Director, Officer (President and CEO), 10% Owner | 4 | Employee Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +231,000 231,000 owned after | $2.85 exercise price | 2007-05-08 | |
| 2006-07-20 holding as of filing | MORRIS I WISTAR III Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-20 | ||
| 2006-07-19 holding as of filing | DELAPE FRANK M Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct · (m) | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | SLATTERY FRANK P JR Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Lewis Michael E Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | KELLEY WILLAM N Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | O MALLEY SHAUN Director | 3 | Nonqualified Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Eringis Dawn Officer (Vice President, Bus. Devel.) | 3 | Employee Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Landekic Nicholas Director, Officer (President and CEO) | 3 | Employee Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Landekic Nicholas Director, Officer (President and CEO) | 3 | Employee Stock Options (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Scott Richard W Officer (Vice President, Research) | 3 | EmployeeStock Options (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 | ||
| 2006-07-19 holding as of filing | Smith Edward F Officer (Chief Financial Officer) | 3 | Employee Stock Option (right to buy) Derivative · Direct | Holding | $1.50 exercise price | 2006-07-19 |